Amendments to the Claims

1. (currently amended) A method for the treatment of a disorder of the eye comprising:

administering to a subject a therapeutically effective amount of a composition comprising a dsRNA between 21 and 23 nucleotides in length and a carrier, said dsRNA having a nucleotide sequence corresponding to mRNA of SEQ ID NO: 3; said administering of the composition occurring outside the blood-retina barrier, and said composition inhibiting mRNA expression of SEQ ID NO: 3 by RNA interference inside the eye.

2.-3. (canceled)

4. (previously presented) The method of claim 1, wherein said disorder is related to angiogenesis and/or neovascularization.

5. (previously presented) The method of claim 1, wherein said disorder is related to the retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.

6. (previously presented) The method of claim 1, wherein said disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.

7.-8. (canceled)

9. (previously presented) The method of claim 1, wherein said dsRNA is an inhibitor of expression of SEQ ID NO: 3.

10. (canceled)

11.-15. (canceled)

16. (previously presented) The method of claim 1, wherein the dsRNA comprises a terminal 3'-hydroxyl group.

17.-93. (canceled)

94. (withdrawn) The method of claim 1, further comprising preparing the dsRNA.

95. (withdrawn) The method of claim 1, further comprising diagnosing a subject with a disorder or a predisposition to a disorder of the eye.

96. (previously presented)The method of claim 1, further comprising detecting a product of SEQ ID NO: 3.

97. (withdrawn) The method of claim 1, further comprising isolating the target gene.

98. (previously presented) The method of claim 1, wherein said administering is by systemic administration.

99. (New) The method of claim 1, wherein said disorder is autosomal recessive retinitis pigmentosa or congenital stationary night blindness.